113 completed, 15 unknown, 12 terminated, 10 recruiting. 159 Phase 1, 42 Phase 2.
Follow Embolism and Thrombosis: new trials by email Literature Review of Embolism and Thrombosis trials Research Report on Embolism and Thrombosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ" Anakinra 100Mg/0.67Ml Inj Syringe - Pancreatic Transplant | Phase 1 / Phase 2 | Recruiting | Nantes University Hospital | 15 | 2026-10-07 | 2026-10-13 |
| Safely Quenching Complement in Stroke Survivors Pegcetacoplan Injection [Empaveli] - Acute Ischemic Stroke, Cerebral Infarction | Phase 1 | Not yet recruiting | Columbia University | 20 | 2026-10-01 | 2026-04-29 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis REGN9933, REGN7508, REGN9533 - End-Stage Kidney Disease (ESKD) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 36 | 2026-09-17 | 2026-10-06 |
| A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion GenSci148 Injection - Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME) | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 60 | 2026-09-01 | 2026-09-14 |
| A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A ARD001, Placebo - Hemophilia A, Healthy Adult Participants | Phase 1 / Phase 2 | Recruiting | Arditus Pte Ltd | 20 | 2026-08-19 | 2026-10-28 |
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection YKYY033 Injection, YKYY033 Placebo - Venous Thromboembolism (VTE) | Phase 1 | Recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 40 | 2026-07-10 | 2026-08-26 |
| A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis EA5 - Antiphospholipid Syndrome (APS), Thrombosis | Phase 1 | Active not recruiting | Shanghai Lanyi Therapeutics Co., Ltd. | 12 | 2026-05-25 | 2026-06-08 |
| A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism CITY-FXI, Placebo - Factor V Leiden, Prothrombin G20210A | Phase 1 | Recruiting | City Therapeutics | 182 | 2026-01-22 | 2026-09-25 |
| Study to Evaluate CAY001 in Healthy Volunteers CAY001, Placebo - Healthy | Phase 1 | Recruiting | Cayuga Biotech, Inc. | 24 | 2025-12-02 | 2026-05-05 |
| Excretion of Rivaroxaban in Human Breast Milk Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet - Postpartum, VTE Prophylaxis | Phase 1 | Recruiting | Thomas Jefferson University | 10 | 2025-07-01 | 2025-07-17 |
| Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) Inflammation (I), Inflammation (II), Inflammation (III) - Covid19 Virus Infection | Phase 1 / Phase 2 | Recruiting | All Natural Medicine Clinic, LLC | 100 | 2025-01-01 | 2025-02-19 |
| A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration EYE201 - Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD) | Phase 1 / Phase 2 | Completed | EyeBiotech Ltd. | 38 | 2024-11-12 | 2026-08-24 |
| A Study of MK-2060 in Healthy Participants (MK-2060-016) MK-2060, Placebo - Venous Thrombosis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 23 | 2024-10-15 | 2025-05-21 |
| A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 - Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers | Phase 1 | Completed | Bayer | 24 | 2024-10-10 | 2025-02-10 |
| A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion - Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers | Phase 1 | Completed | Bayer | 39 | 2024-09-18 | 2025-02-06 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects SRSD107, Placebo - Thrombus | Phase 1 | Completed | Sirius Therapeutics Co., Ltd. | 48 | 2024-03-29 | 2026-06-17 |
| Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery Direct Oral Anticoagulant., Low Molecular Weight Heparine - Deep Venous Thrombosis | Phase 1 | Active not recruiting | Cairo University | 100 | 2024-03-25 | 2025-08-26 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants SRSD107, Placebo - Thrombosis | Phase 1 | Completed | Sirius Therapeutics Co., Ltd. | 40 | 2024-01-23 | 2025-05-18 |
| A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients . Placebo Comparator: Single dose group, Experimental: Food effect group, Active Comparator: Multiple dose group - Thrombosis, Cardiovascular Diseases | Phase 1 | Completed | Peking University First Hospital | 627 | 2023-06-20 | 2026-06-01 |
| COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS Rivaroxaban, Warfarin - Deep Vein Thrombosis (DVT) | Phase 1 | Completed | Children Hospital and Institute of Child Health, Lahore | 74 | 2023-01-20 | 2025-07-22 |
Showing 20 of 159. Sign in to see all of them.
Thrombosis (63) · Retinal Vein Occlusion (33) · Venous Thrombosis (25) · Venous Thromboembolism (22) · Pulmonary Embolism (15) · Macular Edema (14) · Thromboembolism (12) · Inflammation (6) · Macular Degeneration (6) · Embolism (5) · Stroke (5) · Hemorrhage (4) · Atrial Fibrillation (3) · COVID-19 (3) · Cardiovascular Diseases (3)
Vascular Diseases (158) · Cardiovascular Diseases (156) · Thrombosis (62) · Venous Thrombosis (34) · Eye Diseases (30) · Retinal Diseases (30) · Pathological Conditions, Signs and Symptoms (28) · Pathologic Processes (24) · Thromboembolism (22) · Lung Diseases (21) · Respiratory Tract Diseases (21) · Embolism (16) · Retinal Degeneration (16) · Nervous System Diseases (11)
Rivaroxaban (18) · apixaban (12) · Enoxaparin (10) · Ranibizumab (10) · milvexian (9) · Heparin (4) · Tablets (4) · Tissue Plasminogen Activator (4) · Warfarin (4) · Aspirin (3) · Bevacizumab (3) · Clopidogrel (2) · Dabigatran (2) · Dalteparin (2) · Dexamethasone (2)
Bristol-Myers Squibb (16) · Bayer (9) · Jiangsu HengRui Medicine Co., Ltd. (4) · National Eye Institute (NEI) (4) · Thomas Jefferson University (4) · California Retina Consultants (3) · National Institutes of Health Clinical Center (CC) (3) · Aronora, Inc. (2) · Children's Hospital Los Angeles (2) · Daiichi Sankyo (2) · Diakron Pharmaceuticals (2) · Grifols Therapeutics LLC (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Peter A Campochiaro, MD (2)
United States (82) · China (12) · France (10) · Germany (10) · Belgium (9) · United Kingdom (9) · Canada (8) · Australia (6) · Austria (6) · Israel (5) · Italy (5) · Spain (5) · Japan (4) · Switzerland (4) · Lebanon (3)
Catherine A Cukras, M.D. (2) · Peter A Campochiaro, MD (2) · Qiuyue Qu (2) · Theodore Leng, MD (2) · Walter K Kraft, MD (2) · Ahmad Mansour, MD (1) · Akihiko Taguchi, MD.PhD (1) · Alain Gaudric, MD (1) · Alan H Maurer, MD (1) · Alan Tinmouth, MD (1) · Andrew M Siedlecki, MD (1)
PMID 36912792, PMID 40302153, PMID 15893169, PMID 18025536, PMID 18082503, PMID 18307999, PMID 18360849, PMID 19737719, PMID 20442358, PMID 21319285, PMID 21502572, PMID 23912563, PMID 24053892, PMID 24528331, PMID 24641937, PMID 25001321, PMID 25102193, PMID 25677668, PMID 26658126, PMID 26786296, PMID 27170068, PMID 27292282, PMID 27418609, PMID 29269513, PMID 29452956, PMID 29608533, PMID 29649055, PMID 30534007, PMID 30534008, PMID 30617563, PMID 30700130, PMID 30957581, PMID 31030414, PMID 31324209, PMID 31420317, PMID 31977000, PMID 33356383, PMID 33779986, PMID 33950298, PMID 34656469, PMID 34818873, PMID 34818875, PMID 35222036, PMID 35262846, PMID 35641780, PMID 35906349, PMID 36413425, PMID 36564395, PMID 36861188, PMID 37326942
2015 (4), 2017 (2), 1UG1EY026876-01A1 (1), 1UG1EY028517-01 (1), 2008 (1), 2009 (1), 2014 (1), R01HL109448 (1), R01HL141900 (1)